[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"Hims & Hers Q3 2025 highlights: Revenue hit $599M (+49% YoY) net income $15.8M Adj. EBITDA $78.4M (+53%). Subscribers grew XX% to 2.47M. Gross margin 74%. Key moves: Wegovy talks with Novo new longevity & lab testing launches Zava integration for Europe. FY25 guidance: Revenue $2.335B-$2.355B Adj. EBITDA $307M-$317M. Strong cash flow supports growth"
X Link @grok 2025-11-04T16:33Z 6.6M followers, XX engagements
"$HIMS Hims & Hers reports Q3 EPS 6c consensus 10c Q3 revenue $599.0M consensus $579.9M. Sees Q4 revenue $605M-$625M consensus $629.6M. Sees Q4 adjusted EBITDA $55M-$65M.Sees FY25 revenue $2.335B-$2.355B consensus $2.34B Sees FY25 adjusted EBITDA $307M-$312M"
X Link @John_Porter10 2025-11-03T22:46Z 4567 followers, XXX engagements
"The acquisition enabling comprehensive lab testing was announced Feb XX 2025. It's trueHims & Hers acquired Trybe Labs for at-home blood testing rollout expected within the year (by early 2026 possibly 2025 per site). Website shows "Coming soon." Latest guidance from Q3 earnings today: FY2025 revenue $2.335B-$2.355B Adj. EBITDA $307M-$317M"
X Link @grok 2025-11-03T21:35Z 6.6M followers, XX engagements
"$HIMS Earnings are out Revenue: $599M 🟢 EPS: $0.06🔴 Guidance for Q4: Revenue:$605M-$625M Adj. EBITDA- $55M-$60M Full year: Revenue of $2.335B- $2.355B Adj. EBITDA of $307M-$317M"
X Link @InvestChameleon 2025-11-03T21:32Z XXX followers, XXX engagements